SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Reeves WH, Narain S, Satoh M. Autoantibodies in systemic lupus erythematosus. In: KoopmanWJ, editor. Arthritis and allied conditions: a textbook of rheumatology. 15th ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 1497521.
  • 2
    Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003; 100: 26105.
  • 3
    Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 71123.
  • 4
    Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MG, et al. Coordinate overexpression of interferon-α–induced genes in systemic lupus erythematosus. Arthritis Rheum 2004; 50: 395867.
  • 5
    Zhuang H, Narain S, Sobel E, Lee PY, Nacionales DC, Kelly KM, et al. Association of anti-nucleoprotein autoantibodies with upregulation of type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosus. Clin Immunol 2005; 117: 23850.
  • 6
    Asselin-Paturel C, Brizard G, Chemin K, Boonstra A, O'Garra A, Vicari A, et al. Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J Exp Med 2005; 201: 115767.
  • 7
    Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001; 14: 46170.
  • 8
    Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T cells alive. J Exp Med 1999; 189: 5219.
  • 9
    Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003; 19: 22534.
  • 10
    Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after α-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991; 115: 17883.
  • 11
    Dumoulin FL, Leifeld L, Sauerbruch T, Spengler U. Autoimmunity induced by interferon-α therapy for chronic viral hepatitis. Biomed Pharmacother 1999; 53: 24254.
  • 12
    Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy [review]. Arthritis Rheum 2000; 43: 143142.
  • 13
    Zhuang H, Kosboth M, Lee P, Rice A, Driscoll DJ, Zori R, et al. Lupus-like disease and high interferon levels corresponding to trisomy of the type I interferon cluster on chromosome 9p. Arthritis Rheum 2006; 54: 15739.
  • 14
    Nacionales DC, Kelly KM, Lee PY, Zhuang H, Weinstein JS, Sobel E, et al. Type I interferon production by tertiary lymphoid tissue developing in response to 2, 6, 10, 14 tetramethylpentadecane (pristane). Am J Pathol 2006; 168: 122740.
  • 15
    Satoh M, Reeves WH. Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane. J Exp Med 1994; 180: 23416.
  • 16
    Satoh M, Kumar A, Kanwar YS, Reeves WH. Antinuclear antibody production and immune complex glomerulonephritis in BALB/c mice treated with pristane. Proc Natl Acad Sci U S A 1995; 92: 109348.
  • 17
    Wooley PH, Seibold JR, Whalen JD, Chapdelaine JM. Pristane-induced arthritis: the immunologic and genetic features of an experimental murine model of autoimmune disease. Arthritis Rheum 1989; 32: 102230.
  • 18
    Chowdhary VR, Grande JP, Luthra HS, David CS. Characterization of haemorrhagic pulmonary capillaritis: another manifestation of Pristane-induced lupus. Rheumatology (Oxford) 2007. E-pub ahead of print.
  • 19
    Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, et al. Functional role of type I and type II interferons in antiviral defense. Science 1994; 264: 191821.
  • 20
    Marie I, Durbin JE, Levy DE. Differential viral induction of distinct interferon-α genes by positive feedback through interferon regulatory factor-7. EMBO J 1998; 17: 66609.
  • 21
    Richards HB, Satoh M, Shaw M, Libert C, Poli V, Reeves WH. IL-6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus. J Exp Med 1998; 188: 98590.
  • 22
    Yoshida H, Satoh M, Behney KM, Lee CG, Richards HB, Shaheen VM, et al. Effect of an exogenous trigger on the pathogenesis of lupus in (NZB × NZW)F1 mice. Arthritis Rheum 2002; 46: 223544.
  • 23
    Reeves WH, Satoh M, Lyons R, Nichols C, Narain S. Detection of autoantibodies against proteins and ribonucleoproteins by double immunodiffusion and immunoprecipitation. In: DetrickB, HamiltonRG, FoldsJD, editors. Manual of molecular and clinical laboratory immunology. 7th ed. Washington (DC): American Society of Microbiology Press; 2006. p. 100718.
  • 24
    Johnson RJ, Iida H, Alpers CE, Majesky MW, Schwartz SM, Pritzl P, et al. Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis: α-smooth muscle actin is a marker of mesangial cell proliferation. J Clin Invest 1991; 87: 84758.
  • 25
    Bauer JW, Baechler EC, Petri M, Batliwalla FM, Crawford D, Ortmann WA, et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006; 3: e491.
  • 26
    Dubois B, Barthelemy C, Durand I, Liu YJ, Caux C, Briere F. Toward a role of dendritic cells in the germinal center reaction: triggering of B cell proliferation and isotype switching. J Immunol 1999; 162: 342836.
  • 27
    Jourdan M, Tarte K, Legouffe E, Brochier J, Rossi JF, Klein B. Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur Cytokine Netw 1999; 10: 6570.
  • 28
    Schneider P. The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol 2005; 17: 2829.
  • 29
    Ramanujam M, Wang X, Huang W, Schiffer L, Grimaldi C, Akkerman A, et al. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J Immunol 2004; 173: 352434.
  • 30
    Zhang X, Park CS, Yoon SO, Li L, Hsu YM, Ambrose C, et al. BAFF supports human B cell differentiation in the lymphoid follicles through distinct receptors. Int Immunol 2005; 17: 77988.
  • 31
    Calvani N, Satoh M, Croker BP, Reeves WH, Richards HB. Nephritogenic autoantibodies but absence of nephritis in IL-12p35-deficient mice with pristane-induced lupus. Kidney Int 2003; 64: 897905.
  • 32
    Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404: 9959.
  • 33
    Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002; 3: 8229.
  • 34
    Satoh M, Richards HB, Shaheen VM, Yoshida H, Shaw M, Naim JO, et al. Widespread susceptibility among inbred mouse strains to the induction of lupus autoantibodies by pristane. Clin Exp Immunol 2000; 121: 399405.
  • 35
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 36
    Rozzo SJ, Allard JD, Choubey D, Vyse TJ, Izui S, Peltz G, et al. Evidence for an interferon-inducible gene, Ifi202, in the susceptibility to systemic lupus. Immunity 2001; 15: 43543.
  • 37
    Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH, et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003; 197: 77788.
  • 38
    Mellors RC. Autoimmune disease in NZB/BL mice. I. Pathology and pathogenesis of a model system of spontaneous glomerulonephritis. J Exp Med 1965; 122: 2540.
  • 39
    Hahn BH. Animal models of systemic lupus erythematosus. In: WallaceDJ, HahnBH, QuismorioFP, KlinenbergJR, editors. Dubois' lupus erythematosus. Baltimore: Williams & Wilkins; 1996. p. 33980.
  • 40
    Mathian A, Weinberg A, Gallegos M, Banchereau J, Koutouzov S. IFN-α induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice. J Immunol 2005; 174: 2499506.
  • 41
    Hron JD, Peng SL. Type I IFN protects against murine lupus. J Immunol 2004; 173: 213442.
  • 42
    Pisitkun P, Deane JA, Difilippantonio MJ, Tarasenko T, Satterthwaite AB, Bolland S. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 2006; 312: 166972.
  • 43
    Ronnblom L, Alm GV. An etiopathogenic role for the type I IFN system in SLE. Trends Immunol 2001; 22: 42731.
  • 44
    Clynes R, Dumitru C, Ravetch JV. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 1998; 279: 10524.
  • 45
    Bergtold A, Gavhane A, D'Agati V, Madaio M, Clynes R. FcR-bearing myeloid cells are responsible for triggering murine lupus nephritis. J Immunol 2006; 177: 728795.
  • 46
    Tucci M, Barnes EV, Sobel ES, Croker BP, Segal MS, Reeves WH, et al. Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. Arthritis Rheum 2004; 50: 18429.
  • 47
    Fultz MJ, Vogel SN. Interferon α-induced changes in FcγR-specific mRNA expression and isotype-specific, FcγR-mediated phagocytosis in C3H/OuJ (Lpsn) and C3H/HeJ (Lpsd) macrophages. J Leukoc Biol 1992; 51: 3004.
  • 48
    Vollmer J, Tluk S, Schmitz C, Hamm S, Jurk M, Forsbach A, et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 2005; 202: 157585.
  • 49
    Gautier G, Humbert M, Deauvieau F, Scuiller M, Hiscott J, Bates EE, et al. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J Exp Med 2005; 201: 143546.
  • 50
    Tough DF. Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation. Leuk Lymphoma 2004; 45: 25764.